Clinical Trial Update: Total Neoadjuvant Treatment Plus SHR1210 for High-risk Rectal Cancer and Biomarker Screening Base on Neoantigen [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating total neoadjuvant treatment with SHR1210 for high-risk rectal cancer and biomarker screening based on neoantigen.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• SHR1210 (SHR-1210)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Rectal Cancer | Phase 2 | Status: UNKNOWN